BioPharma Dive - Latest News

Eikon raises $351M in one of the year’s largest biotech venture rounds

The funding comes as Eikon, run by former Merck research chief Roger Perlmutter, has started a Phase 3 trial testing one of its cancer drugs against Keytruda. 

Feb 26, 2025 - 13:13
 0
Eikon raises $351M in one of the year’s largest biotech venture rounds

The funding comes as Eikon, run by former Merck research chief Roger Perlmutter, has started a Phase 3 trial testing one of its cancer drugs against Keytruda. 

Read More

Tags:

Previous Article

With no buyer for Tryvio, Idorsia claws back $100M from a double-asset deal with...

Next Article

BP shows activists are often pushing at an open door

Related Posts

Amgen obesity drug on hold; Regeneron sets first dividend

Amgen obesity drug on hold; Regeneron sets first dividend

Feb 9, 2025  0

Orca Bio to seek approval of T cell transplant after positive trial data

Orca Bio to seek approval of T cell transplant after po...

Mar 17, 2025  0

Ono pays $280M to license Ionis rare disease drug

Ono pays $280M to license Ionis rare disease drug

Mar 12, 2025  0